Summary by Moomoo AI
Novartis has upgraded its mid-term sales guidance from 5% to 6% CAGR for 2023-2028, driven by strong performance of in-market products and upcoming launches. The company also projects 5% CAGR for 2024-2029, with most new products having US exclusivity extending into the 2030s. The company remains on track to achieve core operating income margin of 40%+ by 2027.The company's portfolio features 8 in-market brands with peak sales potential of USD 3-8+ billion each, and over 15 near-term submission-enabling readouts. Novartis has identified 30+ high-value pipeline assets to support mid-single-digit growth beyond 2029. The company maintains its transformation into a pure-play innovative medicines company, focusing on core therapeutic areas.In the past two years, Novartis has executed over 30 strategic deals, primarily in early-stage development. Recent acquisitions include Kate Therapeutics for neuromuscular disorder gene therapies and a collaboration with Ratio Therapeutics for radiotherapeutic development, strengthening their innovative portfolio.
